The MarketWatch News Department was not involved in the creation of this content.-- Nadofaragene firadenovec-vncg received an NCCN Category 2A recommendation for patients with pap ...

Ferring Pharmaceuticals announces that nadofaragene firadenovec-vncg (ADSTILADRIN ®) has been upgraded to a National Comprehensive Cancer Network® (NCCN®) Category 2A recommended option for the ...

Determination of bioequivalence to the Reference Listed Drug is essential for approval of an Abbreviated New Drug Application ...

NRx has received confirmatory FDA minutes from in-person Type C meeting attended by leadership of FDA Division of Psychiatry, FDA Office of Neuroscience, and FDA Center for Drug Evaluation and ...

First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or ...

Texas Gov. Abbott warns of Chinese spying through medical devices, directing health agencies to address cybersecurity risks ...

Poster presentation and conference exhibit will feature early preclinical data on the Company’s fully implantable, autoregulating artificial heart platform ...

Earlier today, Hyperfine Inc. released financial results for the quarter ending December 31, 2025. Before we begin, I'd like to remind that management will make statements during this call that ...

First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfuncti ...

CNN’s 5 Things AM brings you the news you need to know every morning.

Extends the budget period for the ~$2M total NIH grant funding award for DARE-PTB1 through November 2026• DARE-PTB1 targets preterm birth, for which there are no FDA-approved treatment options• Award ...

But for Brooklyn, who lives with spinal muscular atrophy, or SMA, a rare genetic condition that affects muscle strength and ...